Low-dose Trifluridine/Tipiracil With Bevacizumab in mCRC

This is a phase II, single-center, prospective trial aimed to investigate the efficacy and safety of a modified regimen of trifluridine/tipiracil plus bevacizumab in refractory metastatic colorectal cancer. Patients will be treated with trifluridine/tipiracil (17.5 mg/m2 dose orally twice daily, d1-10, every 14-days) plus bevacizumab (5mg/kg dose intravenously once at day 1, every 14-days). The study treatment will be administered until progression of disease, intolerable toxicity or withdraw of consent.

NCT Number	NCT07085169
Lead Sponsor	Ruijin Hospital
Conditions	Colo-rectal Cancer, Third-line and Beyond Therapy, TAS 102, Bevacizumab
Enrollment	50 participants
Start Date	2025-08-01
Primary Completion	2027-08-01 (estimated)
Study Completion	2028-08-01 (estimated)
Updated on ClinicalTrials.gov	2025-07-25